Bausch & Lomb Corp (BLCO) stock
BLCONYSEOphthalmic GoodsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 9/3026% below fair value
$21.09−0.05 (-0.24%)
Close on Nov 13, 2026Market cap $7.54BP/E –Yield –
Bausch & Lomb r&d expenses
Research and development expenses are spending on new products and technology.
Bausch & Lomb's R&D Expenses for the twelve months ending Sep 30, 2026 was $400.00M, up 8.1% year over year. For fiscal 2025 it was $371.00M, up 8.2% from the year before. The highest annual figure on record is $371.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $371.00M | +8.2% |
| FY2024 | Dec 31, 2024 | $343.00M | +5.9% |
| FY2023 | Dec 31, 2023 | $324.00M | +5.5% |
| FY2022 | Dec 31, 2022 | $307.00M | +13.3% |
| FY2021 | Dec 31, 2021 | $271.00M | +7.1% |
| FY2020 | Dec 31, 2020 | $253.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $91.00M | -4.2% |
| Q2 FY2026 | Jun 30, 2026 | $114.00M | +18.8% |
| Q1 FY2026 | Mar 31, 2026 | $101.00M | +17.4% |
| Q4 FY2025 | Dec 31, 2025 | $94.00M | +1.1% |
| Q3 FY2025 | Sep 30, 2025 | $95.00M | +13.1% |
| Q2 FY2025 | Jun 30, 2025 | $96.00M | +14.3% |
| Q1 FY2025 | Mar 31, 2025 | $86.00M | +4.9% |
| Q4 FY2024 | Dec 31, 2024 | $93.00M | +16.3% |
| Q3 FY2024 | Sep 30, 2024 | $84.00M | +2.4% |
| Q2 FY2024 | Jun 30, 2024 | $84.00M | -1.2% |
| Q1 FY2024 | Mar 31, 2024 | $82.00M | +6.5% |
| Q4 FY2023 | Dec 31, 2023 | $80.00M | +2.6% |
| Q3 FY2023 | Sep 30, 2023 | $82.00M | +6.5% |
| Q2 FY2023 | Jun 30, 2023 | $85.00M | +13.3% |
| Q1 FY2023 | Mar 31, 2023 | $77.00M | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $78.00M | +11.4% |
| Q3 FY2022 | Sep 30, 2022 | $77.00M | +22.2% |
| Q2 FY2022 | Jun 30, 2022 | $75.00M | +5.6% |
| Q1 FY2022 | Mar 31, 2022 | $77.00M | +14.9% |
| Q4 FY2021 | Dec 31, 2021 | $70.00M | – |
| Q3 FY2021 | Sep 30, 2021 | $63.00M | – |
| Q2 FY2021 | Jun 30, 2021 | $71.00M | – |
| Q1 FY2021 | Mar 31, 2021 | $67.00M | – |
See a number that looks wrong?